Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05180006
Title Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

Her2-receptor positive breast cancer

triple-receptor negative breast cancer

Therapies

Atezolizumab

Atezolizumab + Pertuzumab + Trastuzumab

Atezolizumab + Ipatasertib

Atezolizumab + Bevacizumab

Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.